Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2024

Open Access 01-12-2024 | Cardiomyopathy | Research

Focal ischemic myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy

Authors: Yang Zhi, Fu-dan Gui, Meng Xue, Yi-tian Long, Wen Miao, You Yi, Liang-chao Gao, Fu Bing, Shu-yue Pan

Published in: BMC Cardiovascular Disorders | Issue 1/2024

Login to get access

Abstract

Background

In patients with hypertrophic cardiomyopathy (HCM), ischemic myocardial fibrosis assessed by late gadolinium enhancement (I-LGE) using cardiovascular magnetic resonance (CMR) have been reported. However, the clinical significance of I-LGE has not been completely understood. We aim to evaluate the I-LGE differ phenotypically from HCM without LGE or nonischemic myocardial fibrosis assessed by late gadolinium enhancement (NI-LGE) in the left ventricle (LV).

Methods

The patients with HCM whom was underwent CMR were enrolled, using cine cardiac magnetic resonance to evaluate LV function and LGE to detect the myocardial fibrosis. Three groups were assorted: 1) HCM without LGE; 2) HCM with LGE involved the subendocardial layer was defined as I-LGE; 3) HCM with LGE not involved the subendocardial layer was defined as NI-LGE.

Results

We enrolled 122 patients with HCM in the present study. LGE was detected in 58 of 122 (48%) patients with HCM, and 22 (18%) of patients reported I-LGE. HCM with I-LGE had increased higher left ventricular mass index (LVMI) (P < 0.0001) than HCM with NI-LGE or without LGE. In addition, HCM with I-LGE had a larger LV end- systolic volume (P = 0.045), lower LV ejection fraction (LVEF) (P = 0.026), higher LV myocardial mass (P < 0.001) and thicker LV wall (P < 0.001) more than HCM without LGE alone. The I-LGE were significantly associated with LVEF (OR: 0.961; P = 0.016), LV mass (OR: 1.028; P < 0.001), and maximal end-diastolic LVWT (OR: 1.567; P < 0.001). On multivariate analysis, LVEF (OR: 0.948; P = 0.013) and maximal end-diastolic LVWT (OR: 1.548; P = 0.001) were associated with higher risk for I-LGE compared to HCM without LGE. Noticeably, the maximal end-diastolic LVWT (OR: 1.316; P = 0.011) was the only associated with NI-LGE compared to HCM without LGE.

Conclusions

I-LGE is not uncommon in patients with HCM. HCM with I-LGE was associated with significant LV hypertrophy, extensive LGE and poor LV ejection fraction. We should consider focal ischemic myocardial fibrosis when applying LGE to risk stratification for HCM.
Literature
1.
2.
go back to reference O’Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:867–74.CrossRefPubMed O’Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:867–74.CrossRefPubMed
3.
go back to reference Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379:655–68.CrossRefPubMed Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379:655–68.CrossRefPubMed
4.
go back to reference Shintani Y, Nakayama T, Masaki A, Yokoi M, Wakami K, Ito T, et al. Clinical impact of the pathological quantification of myocardial fibrosis and infiltrating t lymphocytes using an endomyocardial biopsy in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2022;362:110–7.CrossRefPubMed Shintani Y, Nakayama T, Masaki A, Yokoi M, Wakami K, Ito T, et al. Clinical impact of the pathological quantification of myocardial fibrosis and infiltrating t lymphocytes using an endomyocardial biopsy in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2022;362:110–7.CrossRefPubMed
5.
go back to reference Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol. 2000;35:36–44.CrossRefPubMed Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol. 2000;35:36–44.CrossRefPubMed
6.
go back to reference Ziolkowska L, Boruc A, Sobielarska-Lysiak D, Grzyb A, Petryka-Mazurkiewicz J, Mazurkiewicz Ł, et al. Prognostic significance of myocardial ischemia detected by single-photon emission computed tomography in children with hypertrophic cardiomyopathy. Pediatr Cardiol. 2021;42:960–8.CrossRefPubMedPubMedCentral Ziolkowska L, Boruc A, Sobielarska-Lysiak D, Grzyb A, Petryka-Mazurkiewicz J, Mazurkiewicz Ł, et al. Prognostic significance of myocardial ischemia detected by single-photon emission computed tomography in children with hypertrophic cardiomyopathy. Pediatr Cardiol. 2021;42:960–8.CrossRefPubMedPubMedCentral
7.
go back to reference Malahfji M, Senapati A, Debs D, Angulo C, Zhan Y, Nagueh SF, et al. Examining the impact of inducible ischemia on myocardial fibrosis and exercise capacity in hypertrophic cardiomyopathy. Sci Rep. 2020;10:15977.CrossRefPubMedPubMedCentral Malahfji M, Senapati A, Debs D, Angulo C, Zhan Y, Nagueh SF, et al. Examining the impact of inducible ischemia on myocardial fibrosis and exercise capacity in hypertrophic cardiomyopathy. Sci Rep. 2020;10:15977.CrossRefPubMedPubMedCentral
8.
go back to reference Cardim N, Galderisi M, Edvardsen T, Plein S, Popescu BA, D’Andrea A, et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: An expert consensus of the european association of cardiovascular imaging endorsed by the saudi heart association. Eur Heart J Cardiovasc Imaging. 2015;16:280.CrossRefPubMed Cardim N, Galderisi M, Edvardsen T, Plein S, Popescu BA, D’Andrea A, et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: An expert consensus of the european association of cardiovascular imaging endorsed by the saudi heart association. Eur Heart J Cardiovasc Imaging. 2015;16:280.CrossRefPubMed
9.
go back to reference Rajiah P, Desai MY, Kwon D, Flamm SD. Mr imaging of myocardial infarction. Radiographics. 2013;33:1383–412.CrossRefPubMed Rajiah P, Desai MY, Kwon D, Flamm SD. Mr imaging of myocardial infarction. Radiographics. 2013;33:1383–412.CrossRefPubMed
10.
go back to reference Ambale-Venkatesh B, Lima JA. Cardiac mri: A central prognostic tool in myocardial fibrosis. Nat Rev Cardiol. 2015;12:18–29.CrossRefPubMed Ambale-Venkatesh B, Lima JA. Cardiac mri: A central prognostic tool in myocardial fibrosis. Nat Rev Cardiol. 2015;12:18–29.CrossRefPubMed
11.
go back to reference Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309:896–908.CrossRefPubMed Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309:896–908.CrossRefPubMed
12.
go back to reference Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561–7.CrossRefPubMed Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561–7.CrossRefPubMed
13.
go back to reference Dohy Z, Vereckei A, Horvath V, Czimbalmos C, Szabo L, Toth A, et al. How are ecg parameters related to cardiac magnetic resonance images? Electrocardiographic predictors of left ventricular hypertrophy and myocardial fibrosis in hypertrophic cardiomyopathy. Ann Noninvasive Electrocardiol. 2020;25:e12763.CrossRefPubMedPubMedCentral Dohy Z, Vereckei A, Horvath V, Czimbalmos C, Szabo L, Toth A, et al. How are ecg parameters related to cardiac magnetic resonance images? Electrocardiographic predictors of left ventricular hypertrophy and myocardial fibrosis in hypertrophic cardiomyopathy. Ann Noninvasive Electrocardiol. 2020;25:e12763.CrossRefPubMedPubMedCentral
14.
go back to reference Pagourelias ED, Alexandridis GM, Vassilikos VP. Fibrosis in hypertrophic cardiomyopathy: Role of novel echo techniques and multi-modality imaging assessment. Heart Fail Rev. 2021;26:1297–310.CrossRefPubMed Pagourelias ED, Alexandridis GM, Vassilikos VP. Fibrosis in hypertrophic cardiomyopathy: Role of novel echo techniques and multi-modality imaging assessment. Heart Fail Rev. 2021;26:1297–310.CrossRefPubMed
15.
go back to reference Weng Z, Yao J, Chan RH, He J, Yang X, Zhou Y, et al. Prognostic value of lge-cmr in hcm: A meta-analysis. JACC Cardiovasc Imaging. 2016;9:1392–402.CrossRefPubMed Weng Z, Yao J, Chan RH, He J, Yang X, Zhou Y, et al. Prognostic value of lge-cmr in hcm: A meta-analysis. JACC Cardiovasc Imaging. 2016;9:1392–402.CrossRefPubMed
16.
go back to reference Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012;5:370–7.CrossRefPubMed Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012;5:370–7.CrossRefPubMed
17.
go back to reference Satoh H, Sano M, Suwa K, Saitoh T, Nobuhara M, Saotome M, et al. Distribution of late gadolinium enhancement in various types of cardiomyopathies: Significance in differential diagnosis, clinical features and prognosis. World J Cardiol. 2014;6:585–601.CrossRefPubMedPubMedCentral Satoh H, Sano M, Suwa K, Saitoh T, Nobuhara M, Saotome M, et al. Distribution of late gadolinium enhancement in various types of cardiomyopathies: Significance in differential diagnosis, clinical features and prognosis. World J Cardiol. 2014;6:585–601.CrossRefPubMedPubMedCentral
18.
go back to reference Liu J, Zhao S, Yu S, Wu G, Wang D, Liu L, et al. Patterns of replacement fibrosis in hypertrophic cardiomyopathy. Radiology. 2022;302:298–306.CrossRefPubMed Liu J, Zhao S, Yu S, Wu G, Wang D, Liu L, et al. Patterns of replacement fibrosis in hypertrophic cardiomyopathy. Radiology. 2022;302:298–306.CrossRefPubMed
19.
go back to reference Nucifora G, Muser D, Gianfagna P, Morocutti G, Proclemer A. Systolic and diastolic myocardial mechanics in hypertrophic cardiomyopathy and their link to the extent of hypertrophy, replacement fibrosis and interstitial fibrosis. Int J Cardiovasc Imaging. 2015;31:1603–10.CrossRefPubMed Nucifora G, Muser D, Gianfagna P, Morocutti G, Proclemer A. Systolic and diastolic myocardial mechanics in hypertrophic cardiomyopathy and their link to the extent of hypertrophy, replacement fibrosis and interstitial fibrosis. Int J Cardiovasc Imaging. 2015;31:1603–10.CrossRefPubMed
20.
go back to reference Raman B, Ariga R, Spartera M, Sivalokanathan S, Chan K, Dass S, et al. Progression of myocardial fibrosis in hypertrophic cardiomyopathy: Mechanisms and clinical implications. Eur Heart J Cardiovasc Imaging. 2019;20:157–67.CrossRefPubMed Raman B, Ariga R, Spartera M, Sivalokanathan S, Chan K, Dass S, et al. Progression of myocardial fibrosis in hypertrophic cardiomyopathy: Mechanisms and clinical implications. Eur Heart J Cardiovasc Imaging. 2019;20:157–67.CrossRefPubMed
21.
go back to reference Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130:484–95.CrossRefPubMed Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130:484–95.CrossRefPubMed
22.
go back to reference Habib M, Adler A, Fardfini K, Hoss S, Hanneman K, Rowin EJ, et al. Progression of myocardial fibrosis in hypertrophic cardiomyopathy: A cardiac magnetic resonance study. JACC Cardiovasc Imaging. 2021;14:947–58.CrossRefPubMed Habib M, Adler A, Fardfini K, Hoss S, Hanneman K, Rowin EJ, et al. Progression of myocardial fibrosis in hypertrophic cardiomyopathy: A cardiac magnetic resonance study. JACC Cardiovasc Imaging. 2021;14:947–58.CrossRefPubMed
23.
go back to reference Choi HM, Kim KH, Lee JM, Yoon YE, Lee SP, Park EA, et al. Myocardial fibrosis progression on cardiac magnetic resonance in hypertrophic cardiomyopathy. Heart. 2015;101:870–6.CrossRefPubMed Choi HM, Kim KH, Lee JM, Yoon YE, Lee SP, Park EA, et al. Myocardial fibrosis progression on cardiac magnetic resonance in hypertrophic cardiomyopathy. Heart. 2015;101:870–6.CrossRefPubMed
24.
go back to reference Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: Present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64:83–99.CrossRefPubMed Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: Present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64:83–99.CrossRefPubMed
25.
go back to reference She J, Zhao S, Chen Y, Zeng M, Jin H. Detecting Regional Fibrosis in Hypertrophic Cardiomyopathy: The Utility of Myocardial Strain Based on Cardiac Magnetic Resonance. Acad Radiol. 2023;30(2):230–8.CrossRefPubMed She J, Zhao S, Chen Y, Zeng M, Jin H. Detecting Regional Fibrosis in Hypertrophic Cardiomyopathy: The Utility of Myocardial Strain Based on Cardiac Magnetic Resonance. Acad Radiol. 2023;30(2):230–8.CrossRefPubMed
27.
go back to reference Chevalier C, Wendner M, Suling A, Cavus E, Muellerleile K, Lund G, et al. Association of nt-probnp and hs-ctnt with imaging markers of diastolic dysfunction and focal myocardial fibrosis in hypertrophic cardiomyopathy. Life (Basel). 2022;12(8):1241.PubMed Chevalier C, Wendner M, Suling A, Cavus E, Muellerleile K, Lund G, et al. Association of nt-probnp and hs-ctnt with imaging markers of diastolic dysfunction and focal myocardial fibrosis in hypertrophic cardiomyopathy. Life (Basel). 2022;12(8):1241.PubMed
28.
go back to reference Li Y, Liu J, Cao Y, Han X, Shao G, Zhou X, et al. Predictive values of multiple non-invasive markers for myocardial fibrosis in hypertrophic cardiomyopathy patients with preserved ejection fraction. Sci Rep. 2021;11:4297.CrossRefPubMedPubMedCentral Li Y, Liu J, Cao Y, Han X, Shao G, Zhou X, et al. Predictive values of multiple non-invasive markers for myocardial fibrosis in hypertrophic cardiomyopathy patients with preserved ejection fraction. Sci Rep. 2021;11:4297.CrossRefPubMedPubMedCentral
29.
go back to reference Wu G, Liu J, Wang S, Yu S, Zhang C, Wang D, et al. N-terminal pro-brain natriuretic peptide and sudden cardiac death in hypertrophic cardiomyopathy. Heart. 2021;107:1576–83.CrossRefPubMed Wu G, Liu J, Wang S, Yu S, Zhang C, Wang D, et al. N-terminal pro-brain natriuretic peptide and sudden cardiac death in hypertrophic cardiomyopathy. Heart. 2021;107:1576–83.CrossRefPubMed
30.
go back to reference Zhang ZL, Xu YY, Qin Z, Lu YZ, Liu TD, Zhang L, et al. N-terminal pro-brain natriuretic peptide and adverse outcomes in chinese patients with hypertrophic cardiomyopathy. Biosci Rep. 2022;42(1):BSR 20212098.CrossRef Zhang ZL, Xu YY, Qin Z, Lu YZ, Liu TD, Zhang L, et al. N-terminal pro-brain natriuretic peptide and adverse outcomes in chinese patients with hypertrophic cardiomyopathy. Biosci Rep. 2022;42(1):BSR 20212098.CrossRef
31.
go back to reference Liu J, Wang D, Ruan J, Wu G, Xu L, Jiang W, et al. Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy. BMC Med. 2022;20:21.CrossRefPubMedPubMedCentral Liu J, Wang D, Ruan J, Wu G, Xu L, Jiang W, et al. Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy. BMC Med. 2022;20:21.CrossRefPubMedPubMedCentral
32.
go back to reference Yang S, Zhao K, Yang K, Song J, Yu S, Wang J, Dong Z, Ma X, Yin G, Li J, Cheng H, Lu M, Chen X, Zhao S. Subendocardial Involvement as an Underrecognized LGE Subtype Related to Adverse Outcomes in Hypertrophic Cardiomyopathy. JACC Cardiovasc Imaging. 2023;16(9):1163–77.CrossRefPubMed Yang S, Zhao K, Yang K, Song J, Yu S, Wang J, Dong Z, Ma X, Yin G, Li J, Cheng H, Lu M, Chen X, Zhao S. Subendocardial Involvement as an Underrecognized LGE Subtype Related to Adverse Outcomes in Hypertrophic Cardiomyopathy. JACC Cardiovasc Imaging. 2023;16(9):1163–77.CrossRefPubMed
33.
go back to reference Mahrholdt H, Seitz A. Refining the Prognostic Value of LGE in Hypertrophic Cardiomyopathy: Presence, Extent, and Location-What’s Next? JACC Cardiovasc Imaging. 2023;16(9):1178–80.CrossRefPubMed Mahrholdt H, Seitz A. Refining the Prognostic Value of LGE in Hypertrophic Cardiomyopathy: Presence, Extent, and Location-What’s Next? JACC Cardiovasc Imaging. 2023;16(9):1178–80.CrossRefPubMed
34.
go back to reference Jablonowski R, Fernlund E, Aletras AH, Engblom H, Heiberg E, Liuba P, et al. Regional stress-induced ischemia in non-fibrotic hypertrophied myocardium in young hcm patients. Pediatr Cardiol. 2015;36:1662–9.CrossRefPubMedPubMedCentral Jablonowski R, Fernlund E, Aletras AH, Engblom H, Heiberg E, Liuba P, et al. Regional stress-induced ischemia in non-fibrotic hypertrophied myocardium in young hcm patients. Pediatr Cardiol. 2015;36:1662–9.CrossRefPubMedPubMedCentral
35.
go back to reference Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: The interrelation of disarray, fibrosis, and small vessel disease. Heart. 2000;84:476–82.CrossRefPubMedPubMedCentral Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: The interrelation of disarray, fibrosis, and small vessel disease. Heart. 2000;84:476–82.CrossRefPubMedPubMedCentral
36.
go back to reference Das A, Kelly C, Teh I, Nguyen C, Brown LAE, Chowdhary A, et al. Phenotyping hypertrophic cardiomyopathy using cardiac diffusion magnetic resonance imaging: The relationship between microvascular dysfunction and microstructural changes. Eur Heart J Cardiovasc Imaging. 2022;23:352–62.CrossRefPubMed Das A, Kelly C, Teh I, Nguyen C, Brown LAE, Chowdhary A, et al. Phenotyping hypertrophic cardiomyopathy using cardiac diffusion magnetic resonance imaging: The relationship between microvascular dysfunction and microstructural changes. Eur Heart J Cardiovasc Imaging. 2022;23:352–62.CrossRefPubMed
38.
go back to reference Aguiar Rosa S, Thomas B, Fiarresga A, Papoila AL, Alves M, Pereira R, et al. The impact of ischemia assessed by magnetic resonance on functional, arrhythmic, and imaging features of hypertrophic cardiomyopathy. Frontiers in cardiovascular medicine. 2021;8: 761860.CrossRefPubMedPubMedCentral Aguiar Rosa S, Thomas B, Fiarresga A, Papoila AL, Alves M, Pereira R, et al. The impact of ischemia assessed by magnetic resonance on functional, arrhythmic, and imaging features of hypertrophic cardiomyopathy. Frontiers in cardiovascular medicine. 2021;8: 761860.CrossRefPubMedPubMedCentral
Metadata
Title
Focal ischemic myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy
Authors
Yang Zhi
Fu-dan Gui
Meng Xue
Yi-tian Long
Wen Miao
You Yi
Liang-chao Gao
Fu Bing
Shu-yue Pan
Publication date
01-12-2024
Publisher
BioMed Central
Keyword
Cardiomyopathy
Published in
BMC Cardiovascular Disorders / Issue 1/2024
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-024-03859-2

Other articles of this Issue 1/2024

BMC Cardiovascular Disorders 1/2024 Go to the issue